Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

Introduction Immune checkpoint inhibitors (ICI) are associated with unique immune-related adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and poorly understood toxicity; little data are available regarding either risk of irTCP or the effect of irTCP on clinical outcomes of patients treated with ICI. Methods We conducted a retrospective review of sequential cancer patients treated with ICI between 2011 and 2017 at our institution. All patients who received ICI alone or in combination with other systemic therapy in any line of treatment were included; those with thrombocytopenia >= grade 3 at baseline were excluded. We calculated the incidence of >= grade 3 irTCP and overall survival (OS). Patient factors associated with irTCP were assessed. Results We identified 1,038 patients that met eligibility criteria. Overall, 89 (8.6%) patients developed grade >= 3 thrombocytopenia; eighteen were attributed to ICI (1.73% overall). Patients who developed grade >= 3 irTCP had worse overall survival compared to those whose thrombocytopenia was unrelated to ICI (4.17 vs. 10.8 month; HR. 1.94, 95% CI 1.13, 3.33; log-rank p = 0.0164). Patients with grade >= 3 irTCP also had worse survival compared to those without thrombocytopenia (4.17 vs. 13.31 months; HR 2.22, 95% CI 1.36, 3.62; log-rank p = 0.001). The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy (p = 0.059) and was not associated with cancer type, smoking status, age, gender, race, or line of therapy. Conclusions Unlike other irAEs, we found that irTCP was associated with worse overall survival. The incidence of irTCP appeared lowest among those treated with PD-1/L1 monotherapy.

Automated summary

This study retrospectively reviewed cancer patients treated with ICI between 2011 and 2017, finding that 8.6% of patients developed severe thrombocytopenia, with severe irTCP associated with lower survival rates. The incidence of irTCP was lowest among those receiving PD-1/L1 monotherapy.